You are here: Home » International » News » Companies
Business Standard

Sandoz Inc, Macleods Pharma recall 2 drugs made in India

Also, unspecified number of bottles of tablets used to treat Parkinson's disease manufactured by Macleods Pharmaceuticals are also being recalled

Topics
Pharma Sector

Press Trust of India  |  New York 

Image via Shutterstock
Image via Shutterstock

US drug firm Sandoz Inc is recalling more than 270,000 bottles of hypertension tablets, manufactured by Hyderabad-based Mylan Laboratories, from the American market, a report by USFDA said.

Also, unspecified number of bottles of tablets used to treat Parkinson's disease manufactured by Macleods Pharmaceuticals are also being recalled, according to the USFDA.

Read more from our special coverage on "PHARMA SECTOR"



As many as 277,267 bottles of Candesartan Cilexetil tablets manufactured by Mylan Laboratories are being recalled by Sandoz Inc, for whom they were made, in an ongoing recall due to "failed impurities/degradation specifications; 9 month stability time point," the report said.

The USFDA Enforcement Report for the week of February 17 said that the class III voluntary recall is nationwide.

The other recall is of Pramipexole dihydrochloride tablets manufactured by Baddi-based Macleods Pharmaceuticals. The product is being voluntarily recalled by Macleods Pharma USA for whom it was being manufactured here.

The class II recall is on account of presence of foreign tablets/capsules in the product, the report said.

The ongoing nationwide class II recall is due to "presence of a comingled Carbimazole 5 mg tablet," it added.

Class III recall by the United States Food and Drug Administration (USFDA) is initiated in a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

According to the FDA website, a Class II recall is done in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 22 2016. 21:22 IST
RECOMMENDED FOR YOU
.